Skip to main content

Home/ Dr. Goodyear/ Group items tagged PD-L1

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Nathan Goodyear

Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for No... - 0 views

www.nature.com/...srep13110

PD-1 cancer check point inhibitors PD-L1 CLTA-4 immunotherapy

shared by Nathan Goodyear on 20 Apr 18 - No Cached
  • the lack of immunologic control is recognized as a hallmark of cancer currently
  • Programmed death-1 (PD-1) and its ligand PD-L1 play a key role in tumor immune escape and the formation of tumor microenvironment, closely related with tumor generation and development
  • Blockading the PD-1/PD-L1 pathway could reverse the tumor microenvironment and enhance the endogenous antitumor immune responses.
  • ...4 more annotations...
  • environmental factors, living habits, genetic mutations, dysfunction of the immune system and so on
  • special tumor immune microenvironment
  • cytotoxic T lymphocyte-associated antigen 4 (CLTA-4), Programmed death-1 (PD-1) and its ligands PD-L1 (B7H1) and PD-L2 (B7-DC)
  • CTLA-4 regulates T cell activity in the early stage predominantly, and PD-1 mainly limits the activity of T-cell in the tumor microenvironment at later stage of tumor growth
  • Nathan Goodyear on 20 Apr 18
     
    PD-1 to read.
Nathan Goodyear

Chemotherapy induces tumor immune evasion by upregulation of programmed cell ... - 0 views

www.ncbi.nlm.nih.gov/...PMC5527486

chemotherapy PD-L1 immune system cancer

shared by Nathan Goodyear on 16 Feb 21 - No Cached
  • upregulation of glycolysis in cancer cells, with subsequent exhaustion of glucose in the microenvironment, leading to the death of T cells from starvation
  • PD‐L1 expression promotes the production of interleukin 10, a cytokine involved in the death of activated T cells
  • PD‐L1 expression in tumor tissue might lead to T‐cell exhaustion and unresponsiveness
  • ...1 more annotation...
  • PD‐L1 on cancer cells could induce T‐cell apoptosis through
  • Nathan Goodyear on 16 Feb 21
     
    Chemotherapy found to increase PD-L1 expression in vitro and in vivo studies.
Nathan Goodyear

Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment ... - 0 views

www.ncbi.nlm.nih.gov/...PMC5382272

cancer PD-1 immunotherapy programmed death-1

shared by Nathan Goodyear on 20 Apr 18 - No Cached
  • Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), the first immune checkpoint receptor to be clinically targeted, is exclusively expressed on the surface of CD4+ and CD8+ T cells in lymphatic tissue and is involved in T-cell regulation, proliferation, and tolerance
  • programmed death-1 (PD-1) immune checkpoint inhibitor antibodies, which restores T-cell effector function and augments the host anti-tumor response by blocking the binding of either programmed death-ligand 1 (PD-L1) and/or PD-L2 to PD-1 receptors
  • lung cancer is the first and second cause of cancer mortality in men and women
  • ...1 more annotation...
  • Eighty-five percent of lung cancers are non-small-cell lung cancer (NSCLC)
  • Nathan Goodyear on 20 Apr 18
     
    To read update article on PD-1 and immunotherapy.
Nathan Goodyear

PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and In... - 0 views

www.ncbi.nlm.nih.gov/...PMC6345864

CTC radiation circulating tumor cells

shared by Nathan Goodyear on 13 Apr 20 - No Cached
  • Nathan Goodyear on 13 Apr 20
     
    Radiation increases CTC and PD-L1 expression on the CTC.
Nathan Goodyear

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Com... - 0 views

www.ncbi.nlm.nih.gov/...PMC5572324

cancer PD-1 PDL-1 immune system immunotherapy

shared by Nathan Goodyear on 25 Sep 18 - No Cached
  • Nathan Goodyear on 25 Sep 18
     
    Good review of PD-1 and PDL-1 siganling in the immune system in cancer immunotherapy.
Nathan Goodyear

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multi... - 0 views

www.ncbi.nlm.nih.gov/...PMC5809128

cancer anal cancer nivolumab immunotherapy

shared by Nathan Goodyear on 13 Jul 18 - No Cached
  • Patients received a median of six doses of nivolumab
  • four of the first 12 patients had partial responses
  • Nine (24% [95% CI 15–33]) of 37 patients achieved a response (seven partial responses and two complete responses
  • ...16 more annotations...
  • no treatment-related deaths
  • the most common adverse events were anaemia (26 [70%]), fatigue (25 [68%]), and rash
  • hypothyroidism
  • hypothyroidism
  • nivolumab-related autoimmune hypothyroidism, which resolved after a short course of corticosteroids
  • No grade 3 or 4 adverse events occurred
  • Nivolumab resulted in objective responses in 24% of patients with metastatic SCCA
  • Historically, doublet chemotherapy with cisplatin and fluorouracil has been the most common treatment for patients with metastatic SCCA
  • our results suggest that immune checkpoint blockade agents might extend overall survival beyond currently available therapies, especially if provided early in the disease treatment course
  • the dose of nivolumab we used differs from the 2016 recommendation of a fixed 240 mg every 2 weeks
  • 25% of patients develop distant metastases
  • most patients with localised SCCA are cured by chemoradiation
  • More than 90% of cases of SCCA are linked to prior infection with human papillomavirus (HPV)
  • Within tumour cells, HPV oncoproteins are immunogenic and can trigger an anti-tumour host immune response by recruitment of tumour-infiltrating lymphocytes
  • Tumour cells express PD-L1 and, on binding its inhibitory receptor PD-1 on the surface of T cells, downregulate T-cell activation and thwart the local anti-tumour immune response
  • Nivolumab is a humanised monoclonal antibody against PD-1 that disrupts this interaction, enabling T-cell cytotoxicity. It has activity as a monotherapy in advanced solid cancers, such as head and neck cancer, melanoma, non-small-cell lung cancer, and renal cell carcinoma
  • Nathan Goodyear on 13 Jul 18
     
    study finds nivolumab helpful in some patients with surgically unresectable or metastatic anal cancer.  The dose used was 3 mg/kg every 2 weeks. 
Nathan Goodyear

Immunosuppressive Myeloid Cells Induced by Chemotherapy Attenuate Antitumor CD4+ T-Cell... - 0 views

cancerres.aacrjournals.org/...3441

MDSC chemotherapy myeloid-derived suppressor cells

shared by Nathan Goodyear on 15 Nov 20 - No Cached
  • Nathan Goodyear on 15 Nov 20
     
    This study points to the increase in immunosuppression as a result of chemotherapy induced increase in MDSCs and T reg. This effect is dose dependent.
Nathan Goodyear

Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies - 0 views

cancer immunotherapy PD-1 cannabis PD-L1

shared by Nathan Goodyear on 15 Oct 23 - No Cached
  • Nathan Goodyear on 15 Oct 23
     
    retrospective study finds cannabis decreases response rate in patients receiving immune checkpoint inhibiting therapy.
Nathan Goodyear

Abstract GS2-06: Phase Ib/II study evaluating safety and efficacy of pembrolizumab and ... - 0 views

cancerres.aacrjournals.org/...GS2-06

PD-L1 breast cancer keytruda herceptin

shared by Nathan Goodyear on 25 May 21 - No Cached
  • Nathan Goodyear on 25 May 21
     
    The addition of keytruda to herceptin in herceptin resistant breast cancer shown to b safe and effective in small pilot trial; only abstract available here.
1 - 19 of 19
Showing 20▼ items per page